These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

509 related articles for article (PubMed ID: 30646129)

  • 1. Association of Impaired Cytochrome P450 2D6 Activity Genotype and Phenotype With Therapeutic Efficacy of Primaquine Treatment for Latent Plasmodium vivax Malaria.
    Baird JK; Louisa M; Noviyanti R; Ekawati L; Elyazar I; Subekti D; Chand K; Gayatri A; Instiaty ; Soebianto S; Crenna-Darusallam C; Djoko D; Hasto BD; Meriyenes D; Wesche D; Nelwan EJ; Sutanto I; Sudoyo H; Setiabudy R
    JAMA Netw Open; 2018 Aug; 1(4):e181449. PubMed ID: 30646129
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multiple relapses of Plasmodium vivax malaria acquired from West Africa and association with poor metabolizer CYP2D6 variant: a case report.
    He X; Pan M; Zeng W; Zou C; Pi L; Qin Y; Zhao L; Qin P; Lu Y; Baird JK; Huang Y; Cui L; Yang Z
    BMC Infect Dis; 2019 Aug; 19(1):704. PubMed ID: 31399061
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Several Plasmodium vivax relapses after correct primaquine treatment in a patient with impaired cytochrome P450 2D6 function.
    Martin Ramírez A; Lombardia González C; Soler Maniega T; Gutierrez Liarte Á; Domingo García D; Lanza Suárez M; Bernal Fernández MJ; Rubio JM
    Malar J; 2020 Jul; 19(1):259. PubMed ID: 32680522
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel Insights into Plasmodium vivax Therapeutic Failure: CYP2D6 Activity and Time of Exposure to Malaria Modulate the Risk of Recurrence.
    Silvino ACR; Kano FS; Costa MA; Fontes CJF; Soares IS; de Brito CFA; Carvalho LH; Sousa TN
    Antimicrob Agents Chemother; 2020 Apr; 64(5):. PubMed ID: 32122891
    [No Abstract]   [Full Text] [Related]  

  • 5. Four Times of Relapse of Plasmodium vivax Malaria Despite Primaquine Treatment in a Patient with Impaired Cytochrome P450 2D6 Function.
    Choi S; Choi H; Park SY; Kwak YG; Song JE; Shin SY; Baek JH; Shin HI; Oh HS; Kim YC; Yeom JS; Han JH; Kim MJ
    Korean J Parasitol; 2022 Feb; 60(1):39-43. PubMed ID: 35247953
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytochrome P450 2D6 profiles and their relationship with outcomes of primaquine anti-relapse therapy in Australian Defence Force personnel deployed to Papua New Guinea and East Timor.
    Chen N; Dowd S; Gatton ML; Auliff A; Edstein MD; Cheng Q
    Malar J; 2019 Apr; 18(1):140. PubMed ID: 30999967
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics/pharmacodynamics of chloroquine and artemisinin-based combination therapy with primaquine.
    Daher A; Aljayyoussi G; Pereira D; Lacerda MVG; Alexandre MAA; Nascimento CT; Alves JC; da Fonseca LB; da Silva DMD; Pinto DP; Rodrigues DF; Silvino ACR; de Sousa TN; de Brito CFA; Ter Kuile FO; Lalloo DG
    Malar J; 2019 Sep; 18(1):325. PubMed ID: 31547827
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Primaquine ineligibility in anti-relapse therapy of Plasmodium vivax malaria: the problem of G6PD deficiency and cytochrome P-450 2D6 polymorphisms.
    Baird JK; Battle KE; Howes RE
    Malar J; 2018 Jan; 17(1):42. PubMed ID: 29357870
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytochrome P450 2D6 profiles and anti-relapse efficacy of tafenoquine against
    Dowd S; Chen N; Gatton ML; Edstein MD; Cheng Q
    Antimicrob Agents Chemother; 2023 Dec; 67(12):e0101423. PubMed ID: 37971260
    [No Abstract]   [Full Text] [Related]  

  • 10. Impact of CYP2D6 Genetic Variation on Radical Cure of Plasmodium vivax Malaria.
    Suarez-Kurtz G
    Clin Pharmacol Ther; 2021 Sep; 110(3):595-598. PubMed ID: 34042179
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CYP2D6 activity and the risk of recurrence of Plasmodium vivax malaria in the Brazilian Amazon: a prospective cohort study.
    Brasil LW; Rodrigues-Soares F; Santoro AB; Almeida ACG; Kühn A; Ramasawmy R; Lacerda MVG; Monteiro WM; Suarez-Kurtz G
    Malar J; 2018 Feb; 17(1):57. PubMed ID: 29390987
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monoamine oxidase-A (MAO-A) low-expression variants and increased risk of Plasmodium vivax malaria relapses.
    Puça MCSB; Rodrigues DF; Salazar YEAR; Louzada J; Fontes CJF; Daher A; Pereira DB; Fernandes Vieira JL; Carvalho LH; Alves de Brito CF; Gil JP; Nobrega de Sousa T
    J Antimicrob Chemother; 2024 Aug; 79(8):1985-1989. PubMed ID: 38870082
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association between CYP2D6 phenotype and recurrence of Plasmodium vivax infection in south Korean patients.
    Choi S; Choi H; Park SY; Kwak YG; Song JE; Shin SY; Baek JH; Shin HI; Cho SH; Lee SE; Kwon JR; Park S; Kim M; Oh HS; Kim YC; Kim MJ; Yeom JS
    Malar J; 2022 Oct; 21(1):289. PubMed ID: 36217154
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Primaquine treatment and relapse in Plasmodium vivax malaria.
    Rishikesh K; Saravu K
    Pathog Glob Health; 2016; 110(1):1-8. PubMed ID: 27077309
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Case report: recurrence of Plasmodium vivax malaria due to defective cytochrome P450 2D6 function in Pos Lenjang, Pahang, Malaysia.
    Mat Salleh NH; Rahman MFA; Samsusah S; De Silva JR; Ng DC; Ghozali AH; Tan JH; Lai MY; Amir A; Liew JWK; Lau YL
    Trans R Soc Trop Med Hyg; 2020 Sep; 114(9):700-703. PubMed ID: 32511702
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tafenoquine treatment of Plasmodium vivax malaria: suggestive evidence that CYP2D6 reduced metabolism is not associated with relapse in the Phase 2b DETECTIVE trial.
    St Jean PL; Xue Z; Carter N; Koh GC; Duparc S; Taylor M; Beaumont C; Llanos-Cuentas A; Rueangweerayut R; Krudsood S; Green JA; Rubio JP
    Malar J; 2016 Feb; 15():97. PubMed ID: 26888075
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized, open-label trial of primaquine against vivax malaria relapse in Indonesia.
    Sutanto I; Tjahjono B; Basri H; Taylor WR; Putri FA; Meilia RA; Setiabudy R; Nurleila S; Ekawati LL; Elyazar I; Farrar J; Sudoyo H; Baird JK
    Antimicrob Agents Chemother; 2013 Mar; 57(3):1128-35. PubMed ID: 23254437
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of CYP2D6 genotypes on Plasmodium vivax recurrence after primaquine treatment: A meta-analysis.
    Park YA; Park KH; Yoon HY; Yee J; Gwak HS
    Travel Med Infect Dis; 2022; 48():102333. PubMed ID: 35452835
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Delayed gametocyte clearance in
    Salazar YEAR; Louzada J; Puça MCSdB; Guimarães LFF; Vieira JLF; Siqueira AMd; Gil JP; Brito CFAd; Sousa TNd
    Antimicrob Agents Chemother; 2024 Apr; 68(4):e0120423. PubMed ID: 38411047
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Primaquine failure and cytochrome P-450 2D6 in Plasmodium vivax malaria.
    Bennett JW; Pybus BS; Yadava A; Tosh D; Sousa JC; McCarthy WF; Deye G; Melendez V; Ockenhouse CF
    N Engl J Med; 2013 Oct; 369(14):1381-2. PubMed ID: 24088113
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 26.